Do MSSP ACOs Result in Improved Outcomes and Lower Costs?
One study suggests that, after accounting for other factors, MSSPs do not have any impact on outcomes or costs.
In the effort to transition to value-based care, ACOs are leading the way. There are over 900 ACO contracts covering 32 million lives in the United States. One major part of that, Medicare Shared Savings Programs (MSSPs) are often cited as an example of a large-scale initiative that saves costs and improves outcomes. But do they?
A new study from researchers at the University of Michigan School of Public Health, and published in the Annals of Internal Medicine, suggests that while most other studies show that MSSP ACOs do result in at least some improved outcomes and lowered costs, accounting for nonrandom clinician exits suggests no real significant outcomes.
Related: Lessons Learned From MSSP ACOs: What Execs Should Know
The reason for the lack of improvement, according to the study, is because higher-cost clinicians and beneficiaries are more likely to exit MSSP ACOs, potentially distorting data on costs and outcomes in other studies.
“Our results suggest that improved quality and spending performance in this voluntary program may have been driven by nonrandom exit of clinicians and their patient panels from the MSSP,” said the authors.
The authors concluded that pruning those high-cost physicians could have significant impact on purported savings and even explain the phenomenon that some have found that MSSP savings increase over time.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Prime Therapeutics Finds No Medical Cost Offsets for GLP-1 Obesity Drugs | AMCP Annual 2025
April 1st 2025A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control group.
Read More
